-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
GS-CA-1
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2189684-45-3.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 2189684-45-3 |
| Description | GS-CA-1 is a novel HIV capsid inhibitor developed by Gilead, which is a promisingly long-acting antiretroviral (ARV) agent. The preclinical study showed that GS-CA-1 could inhibit HIV-1 replication in human peripheral blood mononuclear cells (PBMCs) (EC50 = 140 pM). |
Product Information
| Synonyms | GS CA 1 |
| Molecular Weight | 958.34 |
| Molecular Formula | C41H36ClF8N7O5S2 |
| Canonical SMILES | CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)F)NS(=O)(=O)C4CC4)C(CC5=CC(=CC(=C5)F)F)NC(=O)CN6C7=C(C8CC8C7(F)F)C(=N6)C(F)F)S(=O)(=O)C |
| Purity | 99.94% |
| Solubility | In Vitro: DMSO : 50 mg/mL(52.17 mM;Need ultrasonic) |
| Appearance | White to light yellow (Solid) |
| Application | long-acting antiretroviral (ARV) agent |
| Storage | Powder: -20°C 3 years In solvent: -80°C 6 months -20°C 1 months |
| Complexity | 2030 |
| Exact Mass | 957.1780126 |
| Target | HIV |
| XLogP3-AA | 6.4 |
